- 1、本文档共35页,可阅读全部内容。
- 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
- 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载。
- 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
批准时间:2015-01-08
Savaysa (edoxaban)
药品使用说明书
用于预防心房颤动(房颤)患者发生
中风和全身性栓塞(SE)
HAOEYOU ( 好医友 )
HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use SAVAYSA?
safely and effectively. See full prescribing information for SAVAYSA.
SAVAYSA (edoxaban) tablets for oral use
Initial U.S. Approval: 2015
WARNING (A) REDUCED EFFICACY IN NONVALVULAR ATRIAL FIBRILLA-
TION PATIENTS WITH CREATININE CLEARANCE (CRCL) > 95 ML/MIN
(B) PREMATURE DISCONTINUATION OF SAVAYSA INCREASES THE RISK
OF ISCHEMIC EVENTS
(C) SPINAL/EPIDURAL HEMATOMA
See full prescribing information for complete boxed warning.
(A) REDUCED EFFICACY IN NONVALVULAR ATRIAL FIBRILLATION
PATIENTS WITH CRCL > 95 ML/MIN: SAVAYSA should not be used in
patients with CrCL > 95 mL/min. In the ENGAGE AF-TIMI 48 study, nonval-
vular atrial fibrillation patients with CrCL > 95 mL/min had an increased
rate of ischemic stroke with SAVAYSA 60 mg once daily compared to
patients treated with warfarin. In these patients another anticoagulant
should be used (5.1).
(B) PREMATURE DISCONTINUATION OF SAVAYSA INCREASES THE RISK
OF ISCHEMIC EVENTS: Premature discontinuation of any oral anticoagu-
lant in the absence of adequate alternative anticoagulation increases the
risk of ischemic events. If SAVAYSA is discontinued for a reason other
than pathological bleeding or completion of a course of therapy, consider
coverage with another anticoagulant as described in the transition guid-
ance (2.4, 5.2, 14).
(C) SPINAL/EPIDURAL HEMATOMA: Epidural or spinal hematomas may
occur in patients treated with SAVAYSA who are receiving neuraxial anes-
thesia or undergoing spinal puncture. These hematomas may result in
long-term or permanent paralysis. Consider these risks when scheduling
patients for spinal procedures (5.4).
______________________ INDICATIONS AND USAGE ____________________
SAVAYSA is a factor Xa inhibitor indicated:
To reduce the risk of stroke and systemic embolism (SE) in patients with non-
valv
文档评论(0)